Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Primary TNBC tumor in the presence or absence of SHP2


ABSTRACT: The first bona fide PTP proto-oncogene was the Src-homology 2 domain-containing phosphatase SHP2 (encoded by PTPN11), an ubiquitously expressed PTP that transduces mitogenic, pro-survival, cell fate and/or pro-migratory signals from numerous growth factor-, cytokine- and extracellular matrix receptors. In malignancies, SHP2 is hyperactivated either downstream of oncoproteins or by mutations.We provide analysis of a primary triple-negative breast tumor grown as xenografts in the presence or absence of SHP2 for 30 days. A primary triple-negative breast tumor (BT8) was transduced with a doxycycline-inducible lentiviral vector expressing a CTRL miR or SHP2 miR1 or SHP2 miR2. Cells from each group were injected in immunodeficient mice and after tumor development, the knockdown of SHP2 was induced for 30 days in vivo. At day 30, tumors were dissected and RNA isolated for gene expression analysis.

ORGANISM(S): Homo sapiens

SUBMITTER: Tim Roloff 

PROVIDER: E-GEOD-35118 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.

Aceto Nicola N   Sausgruber Nina N   Brinkhaus Heike H   Gaidatzis Dimos D   Martiny-Baron Georg G   Mazzarol Giovanni G   Confalonieri Stefano S   Quarto Micaela M   Hu Guang G   Hu Guang G   Balwierz Piotr J PJ   Pachkov Mikhail M   Elledge Stephen J SJ   van Nimwegen Erik E   Stadler Michael B MB   Bentires-Alj Mohamed M  

Nature medicine 20120304 4


New cancer therapies are likely to arise from an in-depth understanding of the signaling networks influencing tumor initiation, progression and metastasis. We show a fundamental role for Src-homology 2 domain-containing phosphatase 2 (SHP2) in these processes in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancers. Knockdown of SHP2 eradicated breast tumor-initiating cells in xenograft models, and SHP2 depletion also prevented invasion in three-dimensional  ...[more]

Similar Datasets

2011-12-20 | E-GEOD-34523 | biostudies-arrayexpress
2012-01-16 | GSE35118 | GEO
2011-12-20 | E-GEOD-34524 | biostudies-arrayexpress
2011-12-20 | E-GEOD-34525 | biostudies-arrayexpress
2022-06-23 | GSE182033 | GEO
2011-12-20 | GSE34523 | GEO
2011-12-20 | GSE34524 | GEO
2009-12-05 | E-MEXP-2473 | biostudies-arrayexpress
2010-10-22 | E-GEOD-20465 | biostudies-arrayexpress
2015-03-06 | E-GEOD-50516 | biostudies-arrayexpress